Compare IVR & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVR | ZVRA |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.4M | 766.1M |
| IPO Year | N/A | 2015 |
| Metric | IVR | ZVRA |
|---|---|---|
| Price | $7.58 | $9.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $8.25 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 2.8M | 1.3M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 17.80% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $150.63 | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ $6.63 | $20.87 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $7.10 | $7.16 |
| 52 Week High | $9.50 | $15.04 |
| Indicator | IVR | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 28.04 |
| Support Level | $7.13 | $8.26 |
| Resistance Level | $7.93 | $11.07 |
| Average True Range (ATR) | 0.16 | 0.74 |
| MACD | -0.04 | -0.39 |
| Stochastic Oscillator | 6.06 | 8.85 |
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.